Instinct Bio Completes Business Combination and Launches on NASDAQ as 'BIOT'

Instinct Bio's Landmark NASDAQ Listing

On July 24, 2026, Instinct Bio, a company at the forefront of regenerative medicine and longevity, made a significant step forward by completing its business combination with Relativity Acquisition Corp., a special purpose acquisition company (SPAC). With this merger finalized, Instinct Bio's shares will officially trade on NASDAQ under the ticker symbol 'BIOT'. This listing marks not just a financial milestone but also a strong move into the healthcare frontier known for promoting healthier and longer lives.

The New Era of Longevity and Regenerative Medicine

In today's world, the desire for longevity and wellness is more pronounced than ever. The global longevity wellness market, which includes regenerative medicine and science-based skincare, is projected to increase from approximately $27.6 billion in 2025 to an estimated $67 billion by 2035. Instinct Bio is strategically positioned to capitalize on this burgeoning market, thanks to its robust pipeline of unique stem cell technologies and premium consumer brands.

As a vertically integrated and revenue-generating platform within the regenerative medicine sector, Instinct Bio is one of the very few companies offering investors access to this rapidly evolving industry on a public market level. The company boasts a distinguished leadership team and a streamlined operation that facilitates the transition from research to market.

Vision and Leadership Insights

Yuki Nagano, Chairman and CEO of Instinct Bio, emphasized the significance of this achievement, stating, “Today marks one of the most important milestones in our company's history. However, going public is merely a starting point for our next leap forward. From day one, our mission has been clear: to enable people worldwide to live longer, healthier, and more vibrant lives through the power of regenerative science.” This commitment is now supported by the capital and global recognition that a NASDAQ listing provides.

Tarek K. Tabsh, CEO of Relativity Acquisition Corp., noted, “We explored many opportunities, but Instinct Bio stood out due to its founder-led management, unique technology, and proven commercialization capabilities.” He expressed pride in guiding BIOT into the public sphere, certain that the best days are ahead.

Five Engines of Value Creation

Instinct Bio’s growth strategy will leverage five key engines to drive value creation:
1. Innovative Science: Expanding R&D in proprietary regenerative medicine and stem cell technologies to strengthen its product pipeline.
2. Scaling Manufacturing: Enhancing vertically integrated manufacturing capabilities to meet growing global demand.
3. Premium Commercialization: Accelerating the rollout of premium regenerative and skincare products into new markets and channels.
4. Strategic Expansion: Pursuing impactful partnerships, licensing opportunities, and selected acquisitions to amplify platform reach.
5. Global Outreach: Strengthening governance and public-oriented structures while expanding operations across Asia and into new international markets.

Instinct Bio's Competitive Edge

Instinct Bio's competitive advantage lies in its comprehensive approach, integrating functions that many competitors must build separately. With its unique regenerative technologies, vertically integrated and quality-controlled manufacturing, and a premium consumer brand backed by a disciplined, founder-led management culture, the company is well-equipped to shorten the distance between scientific discovery and commercial products.

As the company embarks on this new chapter, Instinct Bio is dedicated to fulfilling its mission and delivering groundbreaking healthcare solutions. Its NASDAQ debut is not an end but rather a gateway into a vibrant future, rich with opportunities to impact longevity and wellness positively.

For more information about Instinct Bio and its offerings, visit Instinct Bio's website.